Advertisement

The Distress/Protection Vulnerability Model of Quality of Life Impairment Syndrome

  • Michael S. Ritsner
Chapter

Abstract

In this chapter the author describes the conceptual basis of the health related quality of life (HRQL) impairment syndrome in severe mental disorders (SMD) such as schizophrenia, schizoaffective, mood and anxiety disorders. He presents the evidence for its validity, and identifies some likely directions for future research and development. Based on the author’s and his team research contributions and complementary theoretical considerations, the author explores four issues in this chapter: the quality of life concept, interpreting HRQL findings, conceptualizing HRQL impairment in the framework of the Distress/Protection Vulnerability Model (DPV), and implications for future research. Evidence for the concept’s validity is assessed, followed by a discussion of the possible evolvement of the concept, to encompass biologic domains. Finally, there is a review of the research implications of the HRQL impairment concept and the DPV model followed by a discussion of some major areas of unresolved questions for future research

Key words

Health related quality of life Schizophrenia Schizoaffective Mood disorders Distress/Protection Vulnerability model 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Calman KC. Quality of life in cancer patients–an hypothesis. J Med Ethics. 1984; 10:124–127.PubMedGoogle Scholar
  2. 2.
    Maslow, AH. (1962) Toward a Psychology of Being. Van Nostrand, New York.Google Scholar
  3. 3.
    Wolf JRLM. Client needs and quality of life. Psychiatric Rehabilitation Journal, 1997; 20:16–24.Google Scholar
  4. 4.
    Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med, 1996; 334:835–840.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA, 1995; 273: 59–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Smith KW, Avis NE, Assmann SF. Distinguishing between quality of life and health status in quality of life research: A meta-analysis. Quality of Life Research, 1999; 8: 447–459.PubMedCrossRefGoogle Scholar
  7. 7.
    Orley J, Saxena S, Herrman H. Quality of life and mental illness. Reflections from the perspective of the WHOQOL. Br J Psychiatry, 1998; 172:291–293.PubMedGoogle Scholar
  8. 8.
    Fitzgerald PB, Williams CL, Corteling N, et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatrica Scandinavica, 2001; 103:387–392.PubMedCrossRefGoogle Scholar
  9. 9.
    Ruggeri M, Bisoffi G, Fontecedro L, Warner R. Subjective and objective dimensions of quality of life in psychiatric patients: a factor analytical approach: The South Verona Outcome Project 4. British Journal of Psychiatry, 2001; 178: 268–275.PubMedCrossRefGoogle Scholar
  10. 10.
    Khatri N, Romney DM, Pelletier G. Validity of self-reports about quality of life among patients with schizophrenia. Psychiatric Services, 2001; 52: 534–535.PubMedCrossRefGoogle Scholar
  11. 11.
    Kaiser W, Priebe S, Barr W, Hoffmann K, Isermann M, Roder-Wanner UU, Huxley P. Profiles of subjective quality of life in schizophrenic in- and out-patient samples. Psychiatry Research, 1997; 66: 153–166.PubMedCrossRefGoogle Scholar
  12. 12.
    Trauer T, Duckmanton RA, Chiu E. A study of the quality of life of the severely mentally ill. International Journal of Socical Psychiatry, 1998; 44:79–91.CrossRefGoogle Scholar
  13. 13.
    Lobana A, Mattoo SK, Basu D, Gupta N. Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatrica Scandinavica, 2001; 104: 51–55.PubMedCrossRefGoogle Scholar
  14. 14.
    Awad AG, Voruganti LNP, Heselgrave RJ. A Conceptual Model of Quality of Life in Schizophrenia: Description and Preliminary Clinical Validation. Quality of Life Res 1997; 6: 21–26.CrossRefGoogle Scholar
  15. 15.
    Zissi A, Barry MM, Cochrane R. A mediational model of quality of life for individuals with severe mental health problems. Psychological Medicine, 1998; 28: 1221–1230.PubMedCrossRefGoogle Scholar
  16. 16.
    Ritsner M, Modai I, Endicott J, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000, 61: 880–889.PubMedCrossRefGoogle Scholar
  17. 17.
    Ritsner M, Kurs R, Gibel A, Hirschmann S, Shinkarenko E, Ratner Y. Predictors of quality of life in major psychoses: a naturalistic follow-up study. Journal of Clinical Psychiatry, 2003; 64: 308–315.PubMedCrossRefGoogle Scholar
  18. 18.
    Ritsner, M, Kurs, R. Quality-of-Life Impairment in Severe Mental Illness: Focus on Schizoaffective Disorders. In: Schizoaffective Disorder: New Research. Ed. William H. Murray, NOVA Publishers, New York, 2006; pp. 69–107.Google Scholar
  19. 19.
    Ritsner M, Ponizovsky A, Endicott J, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002; 12: 31–38.PubMedCrossRefGoogle Scholar
  20. 20.
    Ritsner M, Ben-Avi I, Ponizovsky A, Timinsky I, Bistrov E, Modai I. Quality of life and coping with schizophrenia symptoms. Qual Life Res., 2003; 12: 1–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis., 2003; 191: 287–294.PubMedCrossRefGoogle Scholar
  22. 22.
    Ritsner M, Gibel A, Ratner Y. Determinants of Changes in Perceived Quality of Life in the Course of Schizophrenia. Qual Life Res. 2006; 15:515–526.PubMedCrossRefGoogle Scholar
  23. 23.
    Ritsner M, Modai I, Kurs R, et al. Subjective Quality of Life Measurements in Severe Mental Health Patients: Measuring Quality of Life of Psychiatric Patients: Comparison Two Questionnaires. Quality Life Research, 2002; 11: 553–561.CrossRefGoogle Scholar
  24. 24.
    Ponizovsky AM, Grinshpoon A, Levav I, Ritsner MS. Life satisfaction and suicidal attempts among persons with schizophrenia. Comprehensive Psychiatry, 2003; 44: 442–447.PubMedCrossRefGoogle Scholar
  25. 25.
    Ritsner, M, Farkas, H, Gibel, A. Satisfaction with quality of life varies with temperament types of patients with schizophrenia. Journal of Nervous and Mental Disease, 2003; 191: 668–674.PubMedCrossRefGoogle Scholar
  26. 26.
    Kurs R, Farkas H, Ritsner M. Quality of life and temperament factors in schizophrenia: comparative study of patients, their siblings and controls. Quality of Life Research, 2005;14: 433–440.PubMedCrossRefGoogle Scholar
  27. 27.
    Ritsner M, Kurs R, Ponizovsky A, Hadjez J. Perceived quality of life in schizophrenia: relationships to sleep quality. Quality of Life Research, 2004;13: 783–791.PubMedCrossRefGoogle Scholar
  28. 28.
    Ritsner, M, Perelroyzen, G, Kurs, R, Ratner, Y, Jabarin, M, Gibel, A. Quality of life outcomes in schizophrenia patients treated with atypical and typical antipsychotic agents: A naturalistic comparative study. International Clinical Psychopharmacology, 2004; 24: 582–591.CrossRefGoogle Scholar
  29. 29.
    Diener E, Diener M. Cross-cultural correlates of life satisfaction and self-esteem. J Pers Soc Psychol., 1995; 68:653–663.PubMedCrossRefGoogle Scholar
  30. 30.
    Barry MM. Well-being and life satisfaction as components of quality of life in mental disorders. In. eds. H Katsching, H Freeman, and N Sartorius, Quality of Life in Mental Disorders. Chichester: John Wiley & Sons, 1997.Google Scholar
  31. 31.
    Hansson L, Middelboe T, Merinder L, Bjarnason O, Bengtsson-Tops A, Nilsson L, Sandlund M, Sourander A, Sorgaard KW, Vinding H. Predictors of subjective quality of life in schizophrenic patients living in the community. A Nordic multicentre study. : International Journal of Social Psychiatry, 1999; 45: 247–258.PubMedGoogle Scholar
  32. 32.
    Diener E, Oishi S, Lucas RE. Personality, culture, and subjective well-being: emotional and cognitive evaluations of life. Annu Rev Psychol., 2003; 54:403–425.PubMedCrossRefGoogle Scholar
  33. 33.
    Eklund M, Backstrom M, Hansson L. Personality and self-variables: important determinants of subjective quality of life in schizophrenia out-patients. Acta Psychiatrica Scandinavica, 2003; 108: 134–143.PubMedCrossRefGoogle Scholar
  34. 34.
    Yanos PT, Moos RH. Determinants of functioning and well-being among individuals with schizophrenia: An integrated model. Clin Psychol Rev. 2006; 27:58–77.PubMedCrossRefGoogle Scholar
  35. 35.
    Ritsner M, Kurs R. Impact of antipsychotic agents and their side effects on the quality of life in schizophrenia. Expert Review and Pharmacoeconomic Outcomes Research, 2002; 2: 89–98.Google Scholar
  36. 36.
    Ritsner M, Kurs R. Quality of life outcomes in mental illness: schizophrenia, mood and anxiety disorders. Expert Review and Pharmacoeconomic Outcomes Research, 2003; 3: 189–199.CrossRefGoogle Scholar
  37. 37.
    Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability–are patients better off? Canadian Journal of Psychiatry, 2004; 49: 297–302.Google Scholar
  38. 38.
    Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica Supplementum, 2005; 427: 29–34.PubMedCrossRefGoogle Scholar
  39. 39.
    Hansson L. Determinants of quality of life in people with severe mental illness. Acta Psychiatr Scand Suppl., 2006; 429:46–50.PubMedCrossRefGoogle Scholar
  40. 40.
    Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit scale. Schizophr. Bull., 1984; 10:388–398.PubMedGoogle Scholar
  41. 41.
    Stone WS, Faraone SV, Seidman LJ, et al. Concurrent validation of schizotaxia: a pilot study. Biol Psychiatry, 2001; 50:434–440.PubMedCrossRefGoogle Scholar
  42. 42.
    Tsuang MT, Stone WS, Gamma F, Faraone SV. Schizotaxia: current status and future directions. Curr Psychiatry Rep., 2003; 5:128–134.PubMedCrossRefGoogle Scholar
  43. 43.
    Erickson DH, Beiser M, Iacono WG, et al. The role of social relationships in the course of first-episode schizophrenia and affective psychosis. Am J Psychiatry., 1989; 146:1456–1461.PubMedGoogle Scholar
  44. 44.
    Bechdolf A, Pukrop R, Kohn D, et al. Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res., 2005; 79:137–143.PubMedCrossRefGoogle Scholar
  45. 45.
    Browne S, Clarke M, Gervin M, et al. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry, 2000; 176:173–176.PubMedCrossRefGoogle Scholar
  46. 46.
    Melle I, Haahr U, Friis S, et al. Reducing the duration of untreated first-episode psychosis – effects on baseline social functioning and quality of life. Acta Psychiatr Scand., 2005; 112:469–473.PubMedCrossRefGoogle Scholar
  47. 47.
    Czernikiewicz A, Gorecka J, Kozak-Sykala A. [Premorbid adjustment and quality of life in schizophrenia]. Pol Merkuriusz Lek., 2005; 19:659–662.Google Scholar
  48. 48.
    Malla A, Payne J. First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophr Bull., 2005; 31:650–671.PubMedCrossRefGoogle Scholar
  49. 49.
    Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. American Journal of Psychiatry, 2005; 162:1171–1178.PubMedCrossRefGoogle Scholar
  50. 50.
    Priebe S, Roeder-Wanner UU, Kaiser W. Quality of life in first-admitted schizophrenia patients: a follow-up study. Psychological Medicine, 2000; 30: 225–230.PubMedCrossRefGoogle Scholar
  51. 51.
    Henkel H, Schmitz M, Berghofer G. [Quality of life of the mentally ill] Wiener medizinische Wochenschrift, 2000; 150:32–36.PubMedGoogle Scholar
  52. 52.
    Huppert JD, Smith TE. Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor. Journal of Nervous and Mental Disease, 2001; 189:669–675.PubMedCrossRefGoogle Scholar
  53. 53.
    Tempier R, Mercier C, Leouffre P, Caron J. Quality of life and social integration of severely mentally ill patients: a longitudinal study. Journal of Psychiatry and Neuroscience, 1997; 22: 249–255.PubMedGoogle Scholar
  54. 54.
    Skantze K. Subjective quality of life and standard of living: a 10-year follow-up of out-patients with schizophrenia. Acta Psychiatrica Scandinavica, 1998; 98:390–399.PubMedGoogle Scholar
  55. 55.
    Kentros MK, Terkelsen K, Hull J, et al. The relationship between personality and quality of life in persons with schizoaffective disorder and schizophrenia. Quality of Life Research, 1997; 6:118–122.PubMedCrossRefGoogle Scholar
  56. 56.
    Hansson L, Eklund M, Bengtsson-Tops A. The relationship of personality dimensions as measured by the temperament and character inventory and quality of life in individuals with schizophrenia or schizoaffective disorder living in the community. Quality of Life Research, 2001;10:133–139.PubMedCrossRefGoogle Scholar
  57. 57.
    Eklund M, Backstrom M. A model of subjective quality of life for outpatients with schizophrenia and other psychoses. Quality of Life Research, 2005; 14: 1157–1168.PubMedCrossRefGoogle Scholar
  58. 58.
    Zubin, J., Spring, S. Vulnerability - a new model of schizophrenia. Journal of Abnormal Psychology, 1977; 88:103–128.CrossRefGoogle Scholar
  59. 59.
    Green MF, Nuechterlein KH. Backward masking performance as an indicator of vulnerability to schizophrenia. Acta Psychiatr Scand Suppl., 1999; 395:34–40.PubMedGoogle Scholar
  60. 60.
    Berner P. Conceptualization of vulnerability models for schizophrenia: historical aspects. Am J Med Genet., 2002;114:938–942.PubMedCrossRefGoogle Scholar
  61. 61.
    Szoke, A., Schurhoff, F., Ferhadian, N., et al. Temperament in schizophrenia: a study of the tridimensional personality questionnaire (TPQ). European Psychiatry, 2002; 17: 379–383.PubMedCrossRefGoogle Scholar
  62. 62.
    Ormel J, Oldehinkel AJ, Vollebergh W. Vulnerability before, during, and after a major depressive episode: a 3-wave population-based study. Arch Gen Psychiatry, 2004; 61:990–996.PubMedCrossRefGoogle Scholar
  63. 63.
    Ritsner, M, Susser, E. Temperament types are associated with weak self-construct, elevated distress, and emotion-oriented coping in schizophrenia: evidence for a complex vulnerability marker? Psychiatry Research, 2004; 128:219–228.PubMedCrossRefGoogle Scholar
  64. 64.
    Jansen LM, Gispen-de Wied CC, Kahn RS. Selective impairments in the stress response in schizophrenic patients. Psychopharmacology (Berl)., 2000; 149:319–325.CrossRefGoogle Scholar
  65. 65.
    Myin-Germeys, I, Jim van, OS, Schwartz, JE, Stone, AA, Delespaul, PA. Emotional reactivity to daily life stress in psychosis. Archives of General Psychiatry, 2001; 58:1093–1208.CrossRefGoogle Scholar
  66. 66.
    Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychological Reviews, 1997; 104: 667–685.CrossRefGoogle Scholar
  67. 67.
    Majewska, MD. Neurosteroids: endogenous bimodal modulators of the GABAa receptor. Mechanisms of action and physiological significance. Prog. Neurobiol., 1992; 38: 379–395.Google Scholar
  68. 68.
    Debonnel G, Bergeron R, de Montigny C. Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors. J Endocrinol, 1996;150 (Suppl):33–42.Google Scholar
  69. 69.
    Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids. J Psychiatr Res, 1997;31:297–314.PubMedCrossRefGoogle Scholar
  70. 70.
    Wen S, Dong K, Onolfo JP, et al., Treatment with dehydroepiandrosterone sulfate increases NMDA receptors in hippocampus and cortex. Eur J Pharmacol 2001; 430:373–374.PubMedCrossRefGoogle Scholar
  71. 71.
    Migues, PV, Johnston, AN, Rose, SP. Dehydroepiandosterone and its sulphate enhance memory retention in day-old chicks. Neuroscience, 2002; 109: 243–251.PubMedCrossRefGoogle Scholar
  72. 72.
    Wolf OT, Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Brain Res Rev 1999; 30:264–288PubMedCrossRefGoogle Scholar
  73. 73.
    Hu Y, Cardounel A, Gursoy E, et al., Anti-stress effects of dehydroepiandrosterone: protection of rats against repeated immobilization stress-induced weight loss, glucocorticoid receptor production, and lipid peroxidation. Biochem Pharmacol., 2000; 59:753–62PubMedCrossRefGoogle Scholar
  74. 74.
    Boudarene, M, Legros, JJ. Study of the stress response: role of anxiety, cortisol and DHEA-S. Encephale, 2002; 28:139–146.PubMedGoogle Scholar
  75. 75.
    Lapchak, PA, Araujo, DM. Preclinical development of neurosteroids as neuroprotective agents for the treatment of neurodegenerative diseases. Int. Rev. Neurobiol., 2001; 46:379–397.PubMedCrossRefGoogle Scholar
  76. 76.
    Ritsner M, Maayan R, Gibel A, et al. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. European Neuropsychopharmacology, 2004; 14: 267–273.PubMedCrossRefGoogle Scholar
  77. 77.
    Ritsner M, Gibel A, Ram E, et al. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur Neuropsychopharmacol., 2006;16:137–146.PubMedCrossRefGoogle Scholar
  78. 78.
    Johnson, MD, Bebb, RA, Sirrs, SM. Uses of DHEA in aging and other disease states. Ageing Res. Rev. , 2002; 1: 29–41.PubMedCrossRefGoogle Scholar
  79. 79.
    Ritsner, MS, Gibel, A, Ratner, Y, et al. Improvement of sustained attention, visual and movement skills, but not clinical symptomatology, following dehydroepiandrosterone augmentation in schizophrenia: a randomized double-blind, placebo-controlled, crossover trial. Journal of Clinical Psychopharmacology 2006; 26:495–499.PubMedCrossRefGoogle Scholar
  80. 80.
    Griebel G, Stemmelin J, Gal CS, Soubrie P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des, 2005; 11:1549–1559.PubMedCrossRefGoogle Scholar
  81. 81.
    Insel TR, Young LJ. The neurobiology of attachment. Nat Rev Neurosci, 2001; 2:129–136.PubMedCrossRefGoogle Scholar
  82. 82.
    Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry, 2003; 54:504–514.PubMedCrossRefGoogle Scholar
  83. 83.
    Wang J, Rao H, Wetmore GS, Perfusion functional MRI reveals cerebral blood flow pattern under psychological stress. Proc Natl Acad Sci U S A, 2005; 102:17804–17809.PubMedCrossRefGoogle Scholar
  84. 84.
    Taylor SF, Phan KL, Britton JC, Liberzon I. Neural response to emotional salience in schizophrenia. Neuropsychopharmacology, 2005; 30:984–995.PubMedCrossRefGoogle Scholar
  85. 85.
    Davidson RJ. Well-being and affective style: neural substrates and biobehavioural correlates. Philos Trans R Soc Lond B Biol Sci., 2004; 359:1395–1411.PubMedCrossRefGoogle Scholar
  86. 86.
    Sala M, Perez J, Soloff P, et al. Stress and hippocampal abnormalities in psychiatric disorders. Eur Neuropsychopharmacol., 2004; 14:393–405.PubMedCrossRefGoogle Scholar
  87. 87.
    Herman JP, Ostrander MM, Mueller NK, Figueiredo H. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron, 2005; 48:175–187.CrossRefGoogle Scholar
  88. 88.
    Phelps EA, LeDoux JE. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol., 2005; 28:228–237.CrossRefGoogle Scholar
  89. 89.
    Schneider F, Weiss U, Kessler C, et al. Differential amygdala activation in schizophrenia during sadness. Schizophr Res., 1998; 34:133–142.PubMedCrossRefGoogle Scholar
  90. 90.
    Rauch SL, Shin LM, Wright CI. Neuroimaging studies of amygdala function in anxiety disorders. Ann N Y Acad Sci., 2003; 985:389–410.PubMedCrossRefGoogle Scholar
  91. 91.
    Shayegan DK, Stahl SM. Emotion processing, the amygdala, and outcome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2005; 29:840–845.PubMedCrossRefGoogle Scholar
  92. 92.
    van Rijn S, Aleman A, Swaab H, Kahn RS. Neurobiology of emotion and high risk for schizophrenia: role of the amygdala and the X-chromosome. Neurosci Biobehav Rev., 2005; 29:385–397.PubMedCrossRefGoogle Scholar
  93. 93.
    Whittle S, Allen NB, Lubman DI, Yucel M. The neurobiological basis of temperament: Towards a better understanding of psychopathology. Neurosci Biobehav Rev., 2005; Nov 8; [Epub ahead of print]Google Scholar
  94. 94.
    Wright CI, Williams D, Feczko E, Neuroanatomical Correlates of Extraversion and Neuroticism. Cereb Cortex, 2006; 16:1809–1819.PubMedCrossRefGoogle Scholar

Copyright information

© springer 2007

Authors and Affiliations

  • Michael S. Ritsner
    • 1
  1. 1.Department of Psychiatry, The Rappaport Faculty of Medicine, Technion - Israel Institute of Technology and Acute DepartmentSha’ar Menashe Mental Health CenterIsrael

Personalised recommendations